Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1595-1606

  Albert, Daniel H ^a   Conway, Richard G ^a   Magoc, Terrance J ^a   Tapang, Paul ^a   Rhein, David A ^a   Luo, Gongjin ^a   Holms, James H ^a   Davidsen, Steven K ^a   Summers, James B ^a   Carter, George W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETOXYMETHYL 3 [1 (N,N DIMETHYLCARBAMOYL) 6 (4 FLUOROPHENYL)INDOL 3 OYL] 1H,3H PYRROLO[1,2 C]THIAZOL 3 YL PYRIDINIUM CHLORIDE; 1 ACETOXYMETHYL 3 [7 [1 (N,N DIMETHYLCARBAMOYL) 6 (4 FLUOROPHENYL) 3 INDOLYL] 1H,3H PYRROLO[1,2 C]THIAZOL 3 YL]PYRIDINIUM CHLORIDE; 6 (4 FLUOROPHENYL) 3 [3 (3 PYRIDYL) 1H,3H PYRROLO[1,2 C]THIAZOL 7 OYL INDOLE 1 CARBOXYLIC ACID DIMETHYLAMIDE; 6 (4 FLUOROPHENYL) 3 [3 (3 PYRIDYL) 1H,3H PYRROLO[1,2 C]THIAZOL 7 YL] 1 INDOLECARBOXYLIC ACID DIMETHYLAMIDE; APAFANT; BEPAFANT; DRUG METABOLITE; DRUG VEHICLE; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FOROPAFANT; MODIPAFANT; PRODRUG; PYRIDINE 1 OXIDE; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; CALCIUM MOBILIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG POTENCY; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; HYPOTENSION; INFLAMMATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; PRIORITY JOURNAL; RABBIT; RAT; SKIN BLOOD VESSEL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE;

ANIMALS; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HUMANS; KINETICS; MICE; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PRODRUGS; PYRIDINIUM COMPOUNDS; RABBITS; RATS; THIAZOLES;

EID: 12644279859     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. BAENZIGER, N. L. AND MAJERUS, P. W.: Isolation of human platelets and platelet surface membranes. Methods Enzymol. 31: 149-155, 1974.
2. BAGGIOLINI, M. AND DEWALD, B.: Stimulus amplification by PAF and LTB4 in human neutrophils. Pharmacol. Res. Commun. 18: 51-59, 1986.
3. BEL, E. H., DE SMET, M., ROSSING, T. H., TIMMERS, M. C., DIJKMAN, J. H. AND STERK, P. J.: The effect of a specific oral PAF-antagonist, MK-287, on antigen-induced early and late asthmatic reactions in man. Am. Rev. Respir. Dis. 143: A811, 1991.
4. BERNAT, A., HERBERT, J. M., SALEL, V., LESPY, L. AND MAFFRAND, J. P.: Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig. J. Lipid Mediat. 51: 41-48, 1992.
5. BODOR, N.: Design of Prodrugs, Chapter 11, ed. by H. Bundgaard, pp. 333-354, Elsevier Science Publishers B. V., New York, 1977a.
6. BODOR, N.: Design of Biopharmaceutical Properties Through Prodrugs and Analogs, Chapter 7, ed. by E. B. Roche, pp. 98-135, Academy of Pharmaceutical Sciences, Washington, 1977b.
7. BRAQUET, P., PAUBERT-BRAQUET, M., BESSIN, P. AND VARGAFTIG, B. B.: Platelet-activating factor: A potential mediator of shock. Adv. Prostaglandin Thromboxane Leukotriene Res. 7: 822-827, 1987a.
8. BRAQUET, P., PAUBERT-BRAQUET, M., KOLTAI, M., BOURGAIN, R., BUSSOLINO, F. AND HOSFORD, D.: Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharmacol. Sci. 10: 23-30, 1989.
9. BRAQUET, P., TOUQUI, L., SHEN, T. Y. AND VARGAFTIG, B. B.: Perspectives in platelet-activating factor research. Pharmacol. Rev. 39: 97-145, 1987b.
10. BUNDGAARD, H., MORK, N. AND HOELGAARD, A.: Enhanced delivery of nalidixic acid through human skin via acyloxymethyl ester prodrugs. Int. J. Pharmacol. 55: 91-97, 1989.
11. CAMUSSI, G., TETTA, C. AND BAGLIONI, C.: The role of platelet-activating factor in inflammation. Clin. Immunol. Immunopathol. 57: 331-338, 1990.
12. CARLSON, R. P., O'NEILL-DAVIS, L. AND CHANG, J.: Pharmacologic modulation of PAF-induced mortality in mice. Agents Actions 21: 379-381, 1987.
13. CASALS-STENZEL, J., MUACEVIC, G. AND WEBER, K.-H.: Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J. Pharmacol. Exp. Ther. 241: 974-981, 1987.
14. CHAO, W. AND OLSON, M. S.: Platelet-activating factor: Receptors and signal transduction. Biochem. J. 292: 617-629, 1993.
15. COOPER, K., FRAY, M. J., RICHARDSON, K. AND STEELE, J.: The Discovery of UK-74505: A Potent and Selective PAF Antagonist, 203rd National Meeting of the American Chemical Society, MEDI-182, San Francisco, 1992.
16. COUGHLAN, A. F., HAU, H., DUNLOP, L. C., BERNDT, M. C. AND HANCOCK, W. W.: P-selection and platelet-activating factor mediate initial endotoxin-induced neutropenia. J. Exp. Med. 179: 329-334, 1994.
17. DAVIDSEN, S. K., SUMMERS, S. B., ALBERT, D. H., HOLMS, J. H., HEYMAN, H. R., MAGOC, T. J., CONWAY, R. G., RHEIN, D. A. AND CARTER, G. W.: N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist. J. Med. Chem. 37: 4423-4429, 1994.
18. DAVIDSEN, S. K., SUMMERS, J. B., SWEENY, D. J., HOLMS, J. H., ALBERT, D. H., CARRERA, G. M., TAPANG, P., MAGOC, T. J., CONWAY, R. G. AND RHEIN, D. A.: Synthesis of active metabolites of indole pyrrolothiazole PAF antagonists. Bioorg. Med. Chem. Lett. 5: 2909-2912, 1995.
19. DERMARKARIAN, R. M., ISRAEL, E., ROSENBERG, M. A., JANSEN, A., DANZIG, M. R., FOURRE, J. AND DRAZEN, J. M.: The effect of SCH-37370, a dual PAF and histamine antagonist, on the bronchoconstriction induced in asthmatics by cold, dry air isocapnic hyperventilation. Am. Rev. Respir. Dis. 143: A812, 1991.
20. DEWALD, B. AND BAGGIOLINI, M.: Evaluation of PAF antagonists using human neutrophils in a microtiter plate assay. Biochem. Pharmacol. 36: 2505-2510, 1987.
21. DHAINAUT, J. F., TENAILLON, A., HEMMER, M., DAMAS, P., LETULZO, Y., RADERMACHER, P., SCHALLER, M. D., SOLET, J. P., WOLFF, M., HOLZAPFEL, L., ZENI, F., MOTIN, J., MIRA, J. P., DE VATHAIRE, F., CRÉTIEN, J. M., MARSAIS, J., GOURLAY, M. L. AND GUINOT, P.: Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN-52021, in reducing mortality of PTS with severe gram-negative sepsis. Am. J. Respir. Crit. Care Med. 151: A447, 1995.
22. DHAINAUT, J. F., TENAILLON, A., LETULZO, U. Y., SCHLEMMER, B., SOLET, J. P., WOLFF, M., HILLZAPFEL, L., ZENI, F., DREYFUSS, D., MIRA, J. P., CRÉTIEN, J. M., LAVERGNE, V. AND GUINOT, P.: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit. Care Med. 22: 1720-1728, 1994.
23. DOEBBER, T. W., Wu, M. S., ROBBINS, J. C., CHOY, B. M., CHANG, M. N. AND SHEN, T. Y.: Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem. Biophys. Res. Commun. 127: 799-808, 1985.
24. FORD-HUTCHINSON, A. W.: Neutrophil aggregating properties of PAF-acether and leukotriene B4. Int. J. Immunopharmacol. 5: 17-21, 1983.
25. FREITAG, A., WATSON, R. M., MATSOS, G., EASTWOOD, C. AND O'BYRNE, P. M.: Effect of a PAF antagonist WEB-2086, on allergen induced asthmatic response. Thorax 48: 594-598, 1993.
26. GAY, J. C.: Mechanism and regulation of neutrophil priming by platelet-activating factor. J. Cell. Physiol. 156: 189-197, 1993.
27. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440-3445, 1985.
28. HERBERT, J. M., BERNAT, A. AND VALETTE, G. V.: Biochemical and pharmacological activities of SR 27417, a highly potent, long acting PAF receptor antagonist. J. Pharmacol. Exp. Ther. 259: 44-51, 1991.
29. 3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes. Biochem. Pharmacol. 45: 51-58, 1993.
30. HEUER, H. O., KELLER, B. AND URICH, K.: Action of the ratemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats. Arch. Pharmacol. 343: 546-550, 1991.
31. HOLMS, J. H., DAVIDSEN, S. K., SHEPPARD, G. S., CARRERA, G. M., CURTIN, M. L., HEYMAN, H. R., PIREH, D., STEINMAN, D. H., ALBERT, D. H., CONWAY, R. G., Luo, G. J., MAGOC, T. J., TAPANG, P., RHEIN, D. A. AND SUMMERS, J. B.: Discovery and optimization of indole pyrrolothiazole PAF antagonists. Bioorg. Med. Chem. Lett. 5: 2903-2908, 1995.
32. HONDA, Z., NAKAMURA, M., MIKI, I., MINAMI, M., WATANABE, T., SEYAMA, Y., OKADO, H., TOH, H., ITO, K., MIYAMOTO, T. AND SHIMIZU, T.: Cloning by functional expression of PAF receptor from guinea-pig lung. Nature (Lond.) 349: 342-346, 1991.
33. HWANG, S. B., LI, C. L., LAM, M. H. AND SHEN, T. Y.: Characterization of cutaneous vascular permeability induced by PAF in guinea pigs and rats and its inhibition by PAF receptor antagonists. Lab. Invest. 52: 617-630., 1985.
34. IZUMI, T., HONDA, Z., MUTOH, H., KUME, K. AND SHIMIZU, T.: Regulation and signal transduction of PAF receptor. Adv. Prostaglandin Thromboxane Leukotriene Res. 23: 461-466, 1995.
35. KOLTAI, M., HOSFORD, D., GUINOT, P., ESANU, A. AND BRAQUET, P.: Platelet activating factor. A review of its effects, antagonists and possible future clinical implications. Drugs 42: 9-29, 174-204, 1991.
36. KORCHAK, H. M., VOSSHALL, L. B., HAINES, K. A., WILKENFELD, C., LUNDQUIST, K. F. AND WEISSMANN, G.: Activation of the human neutrophil by calcium-mobilizing ligands. II. Correlation of calcium, diacyl glycerol and phosphatidic acid generation with superoxide anion generation. J. Biol. Chem. 263: 11098-11105, 1988.
37. KUITERT, L. M., HUI, K. P., UTHAYARKUMAR, S., BURKE, W., NEWLAND, A. C., UDEN, S. AND BARNES, N. C.: Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am. Rev. Respir. Dis. 147: 82-86, 1993.
38. LOPEZ DIEZ, F., NIETO, M. L., FERNANDEZ-GALLARDO, S., GIJON, M. A. AND SANCHEZ CRESPO, M.: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J. Clin. Invest. 83: 1733-1740, 1989.
39. MUTOH, H., BITO, H., MINAMI, M., NAKAMURA, M., HONDA, Z., IZUMI, T., NAKATA, R., KURACHI, Y., TERANO, A. AND SHIMIZU, T.: Two different promoters direct expression of two distinct forms of mRNAs of human PAF receptor. FEBS Lett. 322: 129-134, 1993.
40. NAKAMURA, M., HONDA, Z., IZUMI, T., SAKANAKA, C., MUTOH, H., MINAMI, M., BITO, H., SEYAMA, Y., MATSUMOTO, T., NOMA, M. AND SHIMIZU, T.: Molecular cloning and expression of PAF receptor from human leukocytes. J. Biol. Chem. 266: 20400-20405, 1991.
41. NIGAM, S., ESKAFI, S., MULLER, S. AND ZHANG, H.: Evidence for the predominant role of intracellular PAF binding sites in the regulation of phospholipase A2 in human neutrophils. Adv. Prostaglandin Thromb. Leukotriene Res. 23: 471-473, 1995.
42. PRESCOTT, S. M., MCINTYRE, T. M. AND ZIMMERMAN, G. A.: The role of platelet-activating factor in endothelial cells. Thromb. Haemost. 64: 99-103, 1990a.
43. PRESCOTT, S. M., ZIMMERMAN, G. A. AND MCINTYRE, T. M.: Platelet-activating factor. J. Biol. Chem. 265: 17381-17384, 1990b.
44. Qu, X. F., HAYASHI, M., YAMAKI, K. AND OH-ISHI, S. O.: Assessment of vascular permeability increase in the mouse by dye leakage during paw edema. Jpn. J. Pharmacol. 52: 500-503, 1990.
45. RACKOW, E. C. AND ASTIZ, M. E.: Mechanisms and management of septic shock. Crit. Care Clin. 9: 219-237, 1993.
46. SAHOO, S. P., GRAHAM, D. W., ACTON, J., BIFTU, T., BUGIANESI, R. L., GIROTRA, N. N., Kuo, C.-H., PONPIPOM, M. M., DOEBBER, T. W., Wu, M. S., HWANG, S.-B., LAM, M.-H., MACINTYRE, D. E., BACH, T. J., LUELL, S., MEURER, R., DAVIES, P., ALBERTS, A. W. AND CHABALA, J. C.: Synthesis and biological activity of MK 287 (L-680,573): A potent, specific and orally active PAF receptor antagonist. Bioorg. Med. Chem. Lett. 1: 327-332, 1991.
47. SCHILD, H. O.: pA, A new scale for the measurement of drug antagonism. Br. J. Pharmacol. 2: 189-195, 1947.
48. SHAW, J. O., PINCKARD, N., FERRIGNI, K. S., MCMANUS, L. M. AND HANAHAN, D. J.: Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-snglyceryl-3-phosphorylcholine (platelet activating factor). J. Immunol. 127: 1250-1253, 1981.
49. SHEPPARD, G. S., DAVIDSEN, S. K., CARRERA, G. M., PIREH, D., HOLMS, J. H., HEYMAN, H. R., STEINMAN, D. H., CURTIN, M. L., CONWAY, R. G., RHEIN, D. A., ALBERT, D. H., TAPANG, P., MAGOC, T. J. AND SUMMERS, J. B.: Synthesis and evaluation of water-soluble indole pyrrolothiazole PAF antagonists. Bioorg. Med. Chem. Lett. 5: 2913-2918, 1995.
50. SHIMIZU, T., HONDA, Z., NAKAMURA, M., BITO, H. AND IZUMI, T.: PAF receptor and signal transduction. Biochem. Phamacol. 44: 1001-1008, 1992.
51. SMITH, P. K, KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTNER, F. H., PROVENZANS, M. D., FUJIMOTO, E. K., GOEHE, N. M., OLSON, B. J. AND KLENK, D. C.: Measurement of protein using bicinchoninic acid. Anal. Biochem. 150: 76-85, 1985.
52. SNYDER, F.: Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether-linked choline-phospholipids. Med. Res. Rev. 5: 107-140, 1985.
53. SNYDER, F.: Platelet-Activating Factor and Related Lipid Mediators, Plenum Press, New York, 1987.
54. SUMMERS, J. B. AND ALBERT, D. H.: Platelet Activating Factor Antagonists. In Advances in Pharmacology, ed. by J. T. August, M. W. Anders, F. Murad and J. Coyle, pp. 67-168, Academic Press, New York, 1995.
55. SUN, X. M. AND HSUEH, W.: Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice. J. Immunol. 147: 509-514, 1991.
56. 3H]platelet-activating factor binding in human platelets. J Pharmacol. Exp. Ther. 252: 1221-1227, 1990.
57. TAMURA, G., TAKISHIMA, T., MUE, S., MAKINO, S., ITOH, K., MIYAMOTO, T., SHIDA, T. AND NAKAJIMA, S.: Effectiveness of a potent platelet activating factor antagonist, WEB-2086, on asthma: A multicentered, double-blind, placebo-controlled study. Eur. Respir. J. 7(suppl. 18): 752, 1994.
58. TORLEY, L. W., PICKETT, W. C., CARROLL, M. L., KOHLER, C. A., SCHAUB, R. E., WISSNER, A., DE JOY, S. Q., ORONSKY, A. L. AND KERWAR, S. S.: Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob. Agents Chemother. 36: 1971-1977, 1992.
59. VERCELLOTTI, G. M., YIN, H. Q., GUSTAFSON, K. S., NELSON, R. D. AND JACOB, H. S.: Platelet-activating factor primes neutrophil responses to agonists: Role in promoting neutrophil-mediated endothelial damage. Blood 71: 1100-1107, 1988.
60. VON DAIHINE, W., GODTFREDSEN, W. O., ROHOLT, K. AND TYBRING, L.: Pivampicillin, a new orally active ampicillin ester. Antimicrob. Agents Chemother. 1970: 431-437, 1971.
61. WHITTAKER, M., THOMPSON, T. M., SPAVOLD, Z. M., PRICE, M., MILLER, A., GALLOWAY, W. A., FRASER, F., FLOYD, C. D., DRUMMOND, A. H., DAVIDSON, A. H., BOWLES, S. A. AND BEBBINGTON, D. S.: Cyclic ether acetal platelet activating factor (PAF) receptor antagonists. I. 3-Pyridyl derivatives. Bioorg. Med. Chem. Lett. 3: 1493-1498, 1993.
62. WILKENS, J. H., WILKENS, H., UFFMANN, J., BOVERS, J., FABEL, H. AND FROLICH, J. C.: Effects of a PAF antagonist (BN-52063) on bronchoconstriction and platelet activation during exercise induced asthma. Br. J. Clin. Pharmacol. 29: 85-91, 1990.